Journals / Ankara Üniversitesi Eczacılık Fakültesi Dergisi / 2022 / Cilt: 46 - Sayı: 1

CYCLIN DEPENDENT KINASE 4/6 AND INHIBITORS

SİKLİN BAĞIMLI KİNAZ 4/6 VE İNHİBİTÖRLERİ

Pages
193–208
Publication Date
2022-01-29
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, general information about cyclin-dependent kinase 4/6 is given and the advantages and disadvantages of its inhibitors are emphasized.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The cancer is one of the serious health problems with high lethality in our country and also in the world.
📊
Key Findings & Data:One of the innovative approaches is inhibition of cyclin-dependent kinase 4/6.
💡
Conclusion & Impact:In this review, general information about cyclin-dependent kinase 4/6 is given and the advantages and disadvantages of its inhibitors are emphasized.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Antitümör ajan · kanser terapisi · meme kanseri

Abstract

Objective: The cancer is one of the serious health problems with high lethality in our country and also in the world. Breast cancer, the second most common type of cancer, is the most common of death in woman. Many innovative approaches have been discovered in drug treatments by elucidating the mechanisms of cancer cell formation. One of the innovative approaches is inhibition of cyclin-dependent kinase 4/6. In this review, general information about cyclin-dependent kinase 4/6 is given and the advantages and disadvantages of its inhibitors are emphasized.

Özet

Amaç: Kanser; ülkemizde ve dünyada öldürücülüğü yüksek olarak karşımıza çıkan ciddi sağlık sorunlarından biridir. İkinci sıklıkta görülen kanser türü olan meme kanseri kadınlarda en fazla ölüm nedenidir. Kanser hücresinin oluşum mekanizmalarının aydınlatılmasıyla, ilaç tedavilerinde bir çok yenilikçi yaklaşım keşfedilmiştir. Yenilikçi yaklaşımlardan biri de siklin bağımlı kinaz 4/6 inhibisyonudur. Bu derlemede siklin bağımlı kinaz 4/6 hakkında genel bilgiler verilerek, inhibitörlerinin avantaj ve dezantajları üzerinde durulmuştur.

🔖

Cite This Article

ARSLAN, G., ÖNKOL, T., ÖZÇELİK, A. B. (2022). CYCLIN DEPENDENT KINASE 4/6 AND INHIBITORS. Ankara Üniversitesi Eczacılık Fakültesi Dergisi, Cilt: 46 - Sayı: 1, 193–208. https://ajindex.com/articles/384420

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Reece, J. B., Urry, L. A., Cain, M. L., Wasserman, S. A., Minorsky, P. V., Jackson, R. B. (2014). Campbell biology, Boston: Pearson, p.1309
  2. Hochegger, H., Takeda, S., Hunt, T. (2008). Cyclin-dependent kinases and cell-cycle transitions: does one fit all?. Nature Reviews Molecular Cell Biology, 9(11), 910-916. [CrossRef] 3. Shapiro, G. I. (2006). Cyclin-dependent kinase pathways as targets for cancer treatment. Journal of Clinical Oncology, 24(11), 1770-1783
  3. DiPippo, A. J., Patel, N. K., Barnett, C. M. (2016). Cyclin dependent kinase inhibitors for the treatment of breast cancer: past, present, and future. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 36(6), 652-667. [CrossRef] 5. Pardee, A. B. (1974). A restriction point for control of normal animal cell proliferation. Proceedings of the National Academy of Sciences, 71(4), 1286-1290. [CrossRef] 6. Malumbres, M., Barbacid, M. (2005). Mammalian cyclin-dependent kinases. Trends in Biochemical Sciences, 30(11), 630-641. [CrossRef] 7. Sherr, C. J. (1996). Cancer cell cycles. Science, 274(5293), 1672-1677. [CrossRef] 8. Sherr, C. J., Roberts, J. M. (1999). CDK inhibitors: positive and negative regulators of G1-phase progression. Genes & Development, 13(12), 1501-1512. [CrossRef] 9. Baldin, V., Lukas, J., Marcote, M. J., Pagano, M., Draetta, G. (1993). Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes & Development, 7(5), 812-821. [CrossRef] 10. Kasten, M. M., Giordano, A. (1998). pRb and the cdks in apoptosis and the cell cycle. Cell Death & Differentiation, 5(2), 132-140. [CrossRef] 11. Mittnacht, S. (1998). Control of pRB phosphorylation. Current Opinion in Genetics & Development, 8(1), 21-27. [CrossRef] 12. Sherr, C. J. (1994). G1 phase progression: cycling on cue. Cell, 79(4), 551-555. [CrossRef] 13. Harbour, J. W., Dean, D. C. (2000). Chromatin remodeling and Rb activity. Current Opinion in Cell Biology, 12(6), 685-689. [CrossRef] 14. Bartek, J., Lukas, J. (2001). Pathways governing G1/S transition and their response to DNA damage. FEBS Letters, 490(3), 117-122. [CrossRef] 15. Roskoski Jr, R. (2016). Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs. Pharmacological Research, 107, 249-275. [CrossRef] 16. Ruas, M. (1998). The p16/CDKN2A tumor suppressor and its relatives. Biochimica et Boophysica Acta, 1378, 115-177. [CrossRef] 17. Chim, C. S., Liang, R., Fung, T. K., Kwong, Y. L. (2005). Infrequent epigenetic